Here are three notes:
- Comments for discussion are due by Dec. 3, with a focus on the inclusion of certain bulk substances in compounding exemptions under Section 503A of the FD&C Act.
- The committee will review substances such as AOD-9604 for obesity and Thymosin alpha-1 for various infections.
- The event will include presentations from both FDA staff and public participants, who can join in person or online.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
